Manufacturer record
Novo Nordisk A/S Novo Alle: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Novo Nordisk A/S Novo Alle (Karnataka) was declared Not of Standard Quality in April 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: MC76638, Human Growth Hormone Inj. (Norditropin Nordiflex 15mg / 1.5ml) (exp Apr 2024). CDL Kolkata (CDSCO lab) found it not of standard quality: Description. Listed in the April 2024 alert.
Records by type
1 record linked to Novo Nordisk A/S Novo Alle in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Human Growth Hormone Inj. (Norditropin Nordiflex 15mg / 1.5ml) | Batch MC76638Mfg May 2022 · Exp Apr 2024 | DescriptionDescription | CDL KolkataCDSCO lab | Apr 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.